Terms: = Brain cancer AND CD52, CDW52, EDDM5
5 results:
1. Neurotoxicity of antibodies in cancer therapy: A review.
Horta E; Bongiorno C; Ezzeddine M; Neil EC
Clin Neurol Neurosurg; 2020 Jan; 188():105566. PubMed ID: 31731087
[TBL] [Abstract] [Full Text] [Related]
2. Severe B cell-mediated disease activation despite two cycles of alemtuzumab in a patient with multiple sclerosis.
Hyun JW; Kim Y; Kim G; Kim SH; Kim HJ
Mult Scler; 2019 Dec; 25(14):1942-1945. PubMed ID: 30403365
[TBL] [Abstract] [Full Text] [Related]
3. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
Hersh CM; Cohen JA
Immunotherapy; 2014; 6(3):249-59. PubMed ID: 24762071
[TBL] [Abstract] [Full Text] [Related]
4. Rapid generation of human B-cell lymphomas via combined expression of Myc and Bcl2 and their use as a preclinical model for biological therapies.
Leskov I; Pallasch CP; Drake A; Iliopoulou BP; Souza A; Shen CH; Schweighofer CD; Abruzzo L; Frenzel LP; Wendtner CM; Hemann MT; Chen J
Oncogene; 2013 Feb; 32(8):1066-1072. PubMed ID: 22484426
[TBL] [Abstract] [Full Text] [Related]
5. Drug therapy for the treatment of Langerhans cell histiocytosis.
McClain KL
Expert Opin Pharmacother; 2005 Nov; 6(14):2435-41. PubMed ID: 16259575
[TBL] [Abstract] [Full Text] [Related]